PAREXEL Recognized As A 2015 "Training Top 125" By Training Magazine

BOSTON, Feb. 10, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it has been recognized among top U.S. businesses in Training magazine's annual "Training Top 125." PAREXEL earned a place in the ranking this year for developing creative and effective employee learning and development initiatives for their global workforce.

"From traditional instructor-led settings to eLearning environments, PAREXEL provides best-in-class learning products and customized training programs to present employees with valuable career and job skills development," said Albert Siu, Vice President, Learning and Development, PAREXEL. "In the highly complex and regulated drug development environment, having expertly trained employees around the globe is an essential element to help our clients simplify their journey toward bringing new drugs to market for patients."

PAREXEL's comprehensive learning and training programs encompass four primary learning domains including: company culture and strategy; functional competencies; leadership development; and professional development. The Company's standardized instructional design model ensures training programs address the complexities of global clinical trial requirements today, with each program featuring a unique set of performance metrics to measure operational and training effectiveness across the learning disciplines.

"PAREXEL impressed us with its focus on delivering 'the right training, to the right people, at the right time' to ensure its employees are prepared to succeed in their jobs and careers," said Lorri Freifeld, editor-in-chief, Training magazine. "The competition was fierce this year, and PAREXEL's global learning and development initiatives earned it this well-deserved spot in our 2015 ranking."

In addition to training employees, PAREXEL is committed to developing the future, global biopharmaceutical workforce with courses specifically tailored to meet the growing talent needs of the clinical development job market.  Since 2001, the PAREXEL Academy has designed and implemented a wide-range of learning and performance programs tailored to enable clinical research management practices for learners outside of PAREXEL. The PAREXEL Academy has locations in the United States, Europe, and Asia. 

For the last 15 years, Training magazine, the leading business publication for learning and development professionals, has issued its annual "Training Top 125," which ranks companies' excellence in employer-sponsored training and development programs. The ranking is based on myriad benchmarking statistics such as total training budget; percentage of payroll; number of training hours per employee program; goals, evaluation, measurement of outcomes and impact, and workplace surveys; hours of training per employee annually; and detailed formal programs. 

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 81 locations in 51 countries around the world, and has approximately 16,530 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisition of ClinIntel Limited, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 as filed with the Securities and Exchange Commission on November 3, 2014, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Contacts:

Diana Martin, PAREXEL International       
Tel: +1 781-434-5516         
Email: [email protected]                                                                                  

Cristi Barnett, PAREXEL International 
Tel.: +1 781-434-4019 
Email: [email protected]

Matthew Briggs, PAN Communications 
Tel: +1 617-502-4300
Email: [email protected]

Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-NY28175-20150210-1.mp4

SOURCE PAREXEL International Corporation

Related Links

http://www.parexel.com